COPENHAGEN, Denmark, January 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a share buy-back program…
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added…
SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the…
Doubles down on its commitment to connecting the world with the right doctors and advancing healthcare innovation and inclusionNEW YORK,…
Data show favorable safety and tolerability with dosing up to 800 mg for 10 daysPlans to initiate human challenge study…
GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective…
GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option…
Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/…
Burlington, Ontario--(Newsfile Corp. - January 7, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today…
SILVER SPRING, Md., Jan. 6, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration issued draft guidance to provide recommendations…